Aclaris Therapeutics
ACRS
Aclaris Therapeutics (ACRS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.13
- EPS estimate
- −$0.13
- EPS surprise
- +2.18%
- Revenue surprise
- +29.44%
- Revenue
- $1.8M
- Revenue estimate
- $1.4M
- Reported
- Aug 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$0.13 | −$0.13 | +2.18% | $1.8M | SEC |
| Q1 2025 | May 8, 2025 | −$0.15 | −$0.12 | +21.16% | $1.5M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.29 | −$1.01 | −252.28% | $9.2M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.01 | −$0.11 | −1829.82% | $4.3M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.20 | −$0.15 | +26.72% | $2.8M | SEC |
| Q1 2024 | May 7, 2024 | −$0.29 | −$0.24 | +16.00% | $2.4M | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.34 | −$0.02 | +94.19% | $17.6M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.48 | −$0.41 | +14.55% | $9.3M | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.45 | −$0.42 | +6.69% | $1.9M | SEC |
| Q1 2023 | May 8, 2023 | −$0.44 | −$0.42 | +3.87% | $2.5M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.45 | −$0.41 | +7.93% | $7.8M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.39 | −$0.30 | +23.31% | $19.0M | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.36 | −$0.31 | +13.48% | $1.5M | SEC |
| Q1 2022 | May 10, 2022 | −$0.39 | −$0.31 | +21.18% | $1.5M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.37 | −$0.37 | −1.37% | $1.5M | SEC |
| Q3 2021 | Nov 2, 2021 | −$0.28 | −$0.35 | −24.25% | $1.7M | SEC |
| Q2 2021 | Aug 5, 2021 | −$0.28 | −$0.34 | −23.64% | $1.8M | SEC |
| Q1 2021 | May 7, 2021 | −$0.30 | −$0.57 | −87.50% | $1.8M | SEC |
| Q4 2020 | Feb 25, 2021 | −$0.31 | −$0.30 | +2.44% | $1.6M | SEC |
| Q3 2020 | Nov 4, 2020 | −$0.31 | −$0.25 | +20.00% | $1.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Aclaris Therapeutics (ACRS) last report earnings?
Aclaris Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did ACRS beat earnings estimates?
Yes. Aclaris Therapeutics reported EPS of −$0.13 for Q2 2025 against a −$0.13 estimate — a 2.18% beat.
How much revenue did ACRS report last quarter?
Aclaris Therapeutics reported $1.8M in revenue for Q2 2025, against a consensus estimate of $1.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.